Core Viewpoint - The strategic cooperation agreement between Prolog Pharma and Antekang Bio aims to enhance the development and production capabilities in the CDMO (Contract Development and Manufacturing Organization) sector, focusing on innovative drug raw materials and intermediates [1][2]. Group 1 - The agreement establishes a long-term partnership for CDMO projects, allowing both parties to seek additional collaborative opportunities in innovative drug development [1][2]. - Antekang Bio will prioritize Prolog Pharma for CDMO project development and production, ensuring a stable supply and competitive advantage in the market [1]. - Prolog Pharma commits to using the processes and technologies provided by Antekang Bio solely for the collaborative CDMO projects, adhering to relevant Chinese laws and project agreements [1]. Group 2 - The collaboration is expected to expand Prolog Pharma's CDMO business and enhance its competitive position in the industry [2].